Valuation: Exelixis, Inc.

Market Cap 14.07B 12.23B 11.38B 10.45B 19.74B 1,343B 20.04B 134B 52.66B 669B 52.84B 51.67B 2,242B P/E 2026 *
17.6x
P/E 2027 * 15x
Enterprise Value 13.25B 11.52B 10.72B 9.84B 18.59B 1,265B 18.87B 126B 49.59B 630B 49.76B 48.66B 2,111B EV / Sales 2026 *
5.1x
EV / Sales 2027 * 4.23x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day-4.82%
1 week-3.88%
Current month-2.19%
1 month-1.37%
3 months+21.84%
6 months+24.32%
Current year+21.42%
1 week 52.96
Extreme 52.96
56.86
1 month 52.96
Extreme 52.96
57.57
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 9
Extreme 9
57.57
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap.
5/27/26 Free

Director

8,367 0.0033%
2/26/26 Free

General Counsel

23,119 0.0086%
2/26/26 Free

Executive/Senior Manager

40,459 0.0151%
Change 5-day change 1-year change 3-year change Capi.($)
-4.72%-3.88%+46.94%+170.02% 14.07B
+2.35%+0.77%+29.92%+85.38% 55.23B
-0.21%-7.38%+25.34%+63.02% 53.75B
-2.28%+1.74%-15.46%-16.52% 23.48B
-3.20%-8.39%-8.70%+343.39% 22B
+2.49%-1.27%+15.99%-10.53% 19.78B
+0.79%-1.06%+29.29%-33.32% 17.44B
+0.58%-7.23%+24.50%+519.07% 14.66B
+3.41%-7.83%+161.76%+284.91% 13.02B
-6.04%-15.44%+52.21%+124.28% 11.37B
Average -0.69%-1.44%+36.18%+152.97% 24.48B
Weighted average by Cap. -0.11%+0.02%+28.62%+120.93%

Financials

2026 *2027 *
Net sales 2.6B 2.26B 2.1B 1.93B 3.64B 248B 3.7B 24.76B 9.72B 123B 9.75B 9.54B 414B 2.92B 2.54B 2.37B 2.17B 4.1B 279B 4.17B 27.9B 10.95B 139B 10.98B 10.74B 466B
Net income 812M 706M 657M 603M 1.14B 77.51B 1.16B 7.74B 3.04B 38.59B 3.05B 2.98B 129B 942M 819M 762M 700M 1.32B 89.94B 1.34B 8.99B 3.53B 44.78B 3.54B 3.46B 150B
Net Debt -819M -712M -663M -609M -1.15B -78.21B -1.17B -7.81B -3.07B -38.94B -3.08B -3.01B -131B -1.7B -1.47B -1.37B -1.26B -2.38B -162B -2.42B -16.18B -6.35B -80.63B -6.37B -6.23B -270B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-07-31 $53.21 -4.94% 1,440,678
26-07-30 $55.97 +1.16% 2,486,679
26-07-29 $55.33 -2.09% 1,882,518
26-07-28 $56.51 +1.25% 2,489,469
26-07-27 $55.81 +0.79% 2,316,906
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
55.97USD
Average target price
52.07USD
Spread / Average Target
-6.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock